Lilly Finalizes Centessa Acquisition, Bolstering Sleep-Wake Disorder Pipeline
Summary
Eli Lilly has completed its acquisition of Centessa Pharmaceuticals, a move aimed at advancing treatments for sleep-wake disorders. This follows the initial agreement announced on April 1st, 2026, regarding assets from Centessa. The completion allows Lilly to integrate Centessa's pipeline and intellectual property, strengthening its position in a key therapeutic area.
At the time of this announcement, LLY was trading at $1,112.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.